Late Breaking Abstract - Protection by budesonide against clinically important deteriorations (CID) in patients with COPD is dependent on blood eosinophil counts (EOS)

Documenti analoghi

• Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD
  di: Bafadhel, M, et al.
  Pubblicazione: (2018)
• Modelling peripheral blood eosinophils to identify response to budesonide in COPD: a post-hoc analysis
  di: Bafadhel, M, et al.
  Pubblicazione: (2017)
• Investigating blood eosinophil count thresholds in patients with COPD
  di: Russell, R, et al.
  Pubblicazione: (2018)
• Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
  di: Pavord, I, et al.
  Pubblicazione: (2017)
• Case series of long-term macrolide therapy effect on eosinophil count in COPD
  di: Asciak, R, et al.
  Pubblicazione: (2017)